Rain Therapeutics, a US-based biotechnology developer based on research from University of Auckland, closed an $18.4m series A round yesterday featuring the Inventors Fund, managed by the institution’s tech transfer office Auckland UniServices.
The round was led by Biotechnology Value Fund (BVF) and included Perceptive Advisors as well as assorted private investors.
Rain Therapeutics is developing cancer treatments. Its lead candidate, Tarloxotinib, is aimed at a certain, rare type of non-small cell lung cancer that affects approximately 6,500 patients in…
